CXCR4 and pulmonary fibrosis: CXCR4 inhibition has been proposed to have beneficial effects on both the prevention and management of acute respiratory distress syndrome and related cytokine storms, pulmonary fibrosis, and imbalanced angiogenesis in SARS-CoV-2-infected lungs.